151. Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer.
- Author
-
Celus W, Oliveira AI, Rivis S, Van Acker HH, Landeloos E, Serneels J, Cafarello ST, Van Herck Y, Mastrantonio R, Köhler A, Garg AD, Flamand V, Tamagnone L, Marine JC, Di Matteo M, Costa BM, Bechter O, and Mazzone M
- Subjects
- Animals, CD8-Positive T-Lymphocytes immunology, Cell Line, Tumor, Humans, Lung Neoplasms immunology, Lung Neoplasms pathology, Lymphocyte Activation, Melanoma, Experimental immunology, Melanoma, Experimental pathology, Mice, Mice, Inbred C57BL, Mice, Knockout, Nerve Tissue Proteins genetics, Programmed Cell Death 1 Receptor immunology, Receptors, Cell Surface genetics, Tumor Microenvironment immunology, Immunotherapy methods, Lung Neoplasms therapy, Melanoma, Experimental therapy, Nerve Tissue Proteins pharmacology, T-Lymphocytes, Cytotoxic immunology
- Abstract
Cytotoxic T cell (CTL) infiltration of the tumor carries the potential to limit cancer progression, but their exclusion by the immunosuppressive tumor microenvironment hampers the efficiency of immunotherapy. Here, we show that expression of the axon guidance molecule Plexin-A4 ( Plxna4 ) in CTLs, especially in effector/memory CD8
+ T cells, is induced upon T-cell activation, sustained in the circulation, but reduced when entering the tumor bed. Therefore, we deleted Plxna4 and observed that Plxna4 -deficient CTLs acquired improved homing capacity to the lymph nodes and to the tumor, as well as increased proliferation, both achieved through enhanced Rac1 activation. Mice with stromal or hematopoietic Plxna4 deletion exhibited enhanced CTL infiltration and impaired tumor growth. In a melanoma model, adoptive transfer of CTLs lacking Plxna4 prolonged survival and improved therapeutic outcome, which was even stronger when combined with anti-programmed cell death protein 1 (PD-1) treatment. PLXNA4 abundance in circulating CTLs was augmented in melanoma patients versus healthy volunteers but decreased after the first cycle of anti-PD-1, alone or in combination with anti-cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), in those patients showing complete or partial response to the treatment. Altogether, our data suggest that Plxna4 acts as a "checkpoint," negatively regulating CTL migration and proliferation through cell-autonomous mechanisms independent of the interaction with host-derived Plxna4 ligands, semaphorins. These findings pave the way toward Plxna4-centric immunotherapies and propose Plxna4 detection in circulating CTLs as a potential way to monitor the response to immune checkpoint blockade in patients with metastatic melanoma., (©2021 The Authors; Published by the American Association for Cancer Research.)- Published
- 2022
- Full Text
- View/download PDF